COMMUNIQUÉS West-GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
11/08/2025
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3 [...]
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
11/08/2025
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to [...]
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
11/08/2025
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
11/08/2025
Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA) DRAGON trial completion expected by Q4 2025 (including a three-month follow-up period) [...]
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
11/08/2025
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s disease 1 Ianalumab [...]
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
11/08/2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a [...]
Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025
11/08/2025
Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 Mont-Saint-Guibert, Belgique – 11 août 2025, 7h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), [...]
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
11/08/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 11, 2025 Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204 * million convertible bonds [...]
AVITA Medical to Host Investor Webinar Briefing
11/08/2025
VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective [...]
RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
10/08/2025
Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive [...]
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
10/08/2025
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 [...]
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
09/08/2025
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum [...]
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
09/08/2025
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE [...]
XORTX Completes USD $114,500 Private Placement
09/08/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX [...]
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements and Implementation of Cease Trade Order
09/08/2025
Not for dissemination in the United States of America VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that the Alberta Securities [...]
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
08/08/2025
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/08/2025
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Earth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8.7 Million in First Quarter Revenue Following Foundational Quarter of Strategic Acquisitions
08/08/2025
MIAMI, FL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- MIAMI, FL – August 8, 2025 – Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential [...]
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
08/08/2025
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]

Pages